Cerebral lymphoma in an adenosine deaminase-deficient patient with severe combined immunodeficiency receiving polyethylene glycol-conjugated adenosine deaminase

Pediatrics

Volumn 116, Issue 6, 2005, Pages

  Kaufman, David A ^a   Hershfield, Michael S ^b   Bocchini, Joseph A ^a   Moissidis, I John ^a   Jeroudi, Majed ^a   Bahna, Sami L ^a  

^a Louisiana State University School of Medicine Shreveport   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

ADA deficiency; Immunodeficiency; Lymphoma; PEG ADA; Severe combined immunodeficiency

Indexed keywords

ADENOSINE DEAMINASE; ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MACROGOL; MERCAPTOPURINE; METHOTREXATE; PHENYTOIN; PREDNISONE; VINCRISTINE; DRUG CARRIER; PEGADEMASE BOVINE;

ANAMNESIS; ARTICLE; BLOOD CELL COUNT; BRAIN ABSCESS; BRAIN BIOPSY; BRAIN LYMPHOMA; CASE REPORT; CLINICAL FEATURE; COMBINED IMMUNODEFICIENCY; DRUG MEGADOSE; ENZYME DEFICIENCY; EPSTEIN BARR VIRUS; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; LABORATORY TEST; MALE; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOSCOPY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SCHOOL CHILD; BRAIN TUMOR; CHILD; FATALITY; LYMPHOMA; VIRUS INFECTION;

ADENOSINE DEAMINASE; BRAIN NEOPLASMS; CHILD; DRUG CARRIERS; EPSTEIN-BARR VIRUS INFECTIONS; FATAL OUTCOME; HUMANS; LYMPHOMA; MALE; SEVERE COMBINED IMMUNODEFICIENCY;

EID: 33644696863     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2005-1068     Document Type: Article

References (23)

1. Hershfield MS, Mitchell BS. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 2001:2585-2625
2. Hershfield MS. Combined immune deficiencies due to purine enzyme defects. In: Stiehm ER, Ochs HD, Winkelstein JA, eds. Immunologic Disorders in Infants and Children. Philadelphia, PA: WB Saunders; 2004:480-504
3. Hershfield MS, Buckley RH, Greenberg ML, et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med. 1987;316:589-596
4. Hershfield MS. PEG-ADA: an alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency. Hum Mut. 1995;5:107-112
5. Santisteban I, Arredondo-Vega FX, Kelly S, et al. Four new adenosine deaminase mutations, altering a zinc-binding histidine, two conserved alanines, and a 5′ splice site. Hum Mutat. 1995;5:243-250
6. Buckley RH. Primary immunodeficiency diseases. In: Adkinson NF Jr, Yunginger JW, Busse WW, Bochner BS, Holgate ST, Simons FER, eds. Middleton's Allergy: Principles and Practice. Philadelphia, PA: Mosby; 2003:1015-1042
7. Hirschhorn R. Adenosine deaminase deficiency: molecular basis and recent developments. Clin Immunol Immunopathol. 1995;76(3 pt 2):S219-S227
8. Wolfson JJ, Cross VF. The radiologic findings in 49 patients with combined immunodeficiency. In: Meuwissen HJ, Pickering RJ, Polara B, Porter IH, eds. Combined Immunodeficiency Disease and Adenosine Deaminase Deficiency: A Molecular Defect. New York, NY: Academic Press; 1975:255-277
9. Ratech H, Greco MA, Gallo G, Rimoin DL, Kamino H, Hirschhorn R. Pathologic findings in adenosine deaminase-deficient severe combined immunodeficiency. I. Kidney, adrenal, and chondro-osseous tissue alterations. Am J Pathol. 1985;120:157-169
10. Stephan JL, Vlekova V, Le Deist F, et al. Severe combined immunodeficiency: a retrospective single center study of clinical presentation and outcome in 117 patients. J Pediatr. 1993;123:564-572
11. Arredondo-Vega FX, Santisteban I, Daniels S, Toutain S, Hershfield MS. Adenosine deaminase deficiency: genotype-phenotype correlations based on expressed activity of 29 mutant alleles. Am J Hum Genet. 1998;63:1049-1059
12. Hirschhorn R, Nicknam MN, Eng F, Yang DR, Borkowsky W. Novel deletion and a new missense mutation (Glu 217 Lys) at the catalytic site in two adenosine deaminase alleles of a patient with neonatal onset adenosine deaminase - severe combined immunodeficiency. J Immunol. 1992;149:3107-3112
13. Filipovich AH, Mathur A, Kamat D, Shapiro RS. Primary immunodeficiency: genetic risk factors for lymphoma. Cancer Res. 1992;52(19 suppl):5465s-5467s
14. Perry GS, Spector BD, Schuman LM, et al. The Wiskott-Aldrich syndrome in the United States and Canada (1892-1979). J Pediatr. 1980;97:72-78
15. Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J Natl Cancer Inst. 1986;77:89-92
16. Cunningham-Rundles C, Siegal FP, Cunningham-Rundles S, Lieberman P. Incidence of cancer in 98 patients with common varied immunodeficiency. J Clin Immunol. 1987;7:294-299
17. Gatti RA, Good RA. Occurrence of malignancy in immunodeficiency diseases: a literature review. Cancer. 1971;28:89-98
18. Knowles DM. Immunodeficiency-associated lymphoproliferative disorders. Mod Pathol. 1999;12:200-217
19. Canioni D, Jabado N, MacIntyre E, Patey N, Emile JF, Brousse N. Lymphoproliferative disorders in children with primary immunodeficiencies: immunological status may be more predictive of the outcome than other criteria. Histopathology. 2001;38:146-159
20. Elenitoba-Johnson KSJ, Jaffe ES. Lymphoproliferative disorders associated with congenital immunodeficiencies. Semin Diagn Pathol. 1997;14:35-47
21. Ohga S, Nomura A, Takada H, et al. Immunological aspects of Epstein-Barr virus infection. Crit Rev Oncol Hematol. 2002;44:203-215
22. Ratech H, Hirschhorn R, Greco MA. Pathologic findings in adenosine deaminase deficient-severe combined immunodeficiency. II. Thymus, spleen, lymph node, and gastrointestinal tract lymphoid tissue alterations. Am J Pathol. 1989;135:1145-1156
23. Gross RG, Steinbuch M, DeFor T, et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment, and outcome. Bone Marrow Transplant. 1999;23:251-258